;PMID: 11592102
;source_file_705.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..138] = [t:36..138]
;2)section:[e:142..213] = [t:142..213]
;3)section:[e:217..323] = [t:217..323]
;4)sentence:[e:327..671] = [t:327..671]
;5)sentence:[e:672..796] = [t:672..796]
;6)sentence:[e:797..994] = [t:797..994]
;7)sentence:[e:995..1154] = [t:995..1154]
;8)sentence:[e:1155..1235] = [t:1155..1235]
;9)sentence:[e:1236..1298] = [t:1236..1298]
;10)sentence:[e:1299..1394] = [t:1299..1394]
;11)sentence:[e:1395..1590] = [t:1395..1590]
;12)sentence:[e:1591..1709] = [t:1591..1709]
;13)section:[e:1710..1748] = [t:1710..1748]
;14)section:[e:1752..1797] = [t:1752..1797]

;section 0 Span:0..31
;J Pathol  2001 Sep;195(2):222-8
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..8] Pathol) (CD:[10..14] 2001)
        (CC:[15..23] Sep;195-LRB-) (CD:[23..24] 2) (-RRB-:[24..25] -RRB-)
        (CD:[25..29] :222) (::[29..30] -) (CD:[30..31] 8)))

;sentence 1 Span:36..138
;beta-catenin nuclear expression correlates with cyclin D1 overexpression in 
;sporadic desmoid tumours.
;[36..48]:gene-protein:"beta-catenin"
;[84..93]:gene-protein:"cyclin D1"
;[113..137]:malignancy:"sporadic desmoid tumours"
(SENT
  (S-HLN
    (NP-SBJ (NN:[36..48] beta-catenin) (JJ:[49..56] nuclear)
            (NN:[57..67] expression))
    (VP (VBZ:[68..78] correlates)
      (PP-CLR (IN:[79..83] with)
        (NP
          (NML (NN:[84..90] cyclin) (NN:[91..93] D1))
          (NN:[94..108] overexpression)))
      (PP-LOC (IN:[109..111] in)
        (NP (JJ:[113..121] sporadic) (JJ:[122..129] desmoid)
            (NNS:[130..137] tumours))))
    (.:[137..138] .)))

;section 2 Span:142..213
;Saito T, Oda Y, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, Tsuneyoshi M.
(SEC
  (FRAG (NNP:[142..147] Saito) (NNP:[148..149] T) (,:[149..150] ,)
        (NNP:[151..154] Oda) (NNP:[155..156] Y) (,:[156..157] ,)
        (NNP:[158..164] Tanaka) (NNP:[165..166] K) (,:[166..167] ,)
        (NNP:[168..175] Matsuda) (NNP:[176..178] S,) (NNP:[179..185] Tamiya)
        (NNP:[186..188] S,) (NNP:[189..196] Iwamoto) (NNP:[197..198] Y)
        (,:[198..199] ,) (NNP:[200..210] Tsuneyoshi) (NNP:[211..213] M.)))

;section 3 Span:217..323
;Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu
; University, Fukuoka, Japan.
(SEC
  (FRAG (NNP:[217..227] Department) (IN:[228..230] of) (NNP:[231..239] Anatomic)
        (NNP:[240..249] Pathology) (,:[249..250] ,) (NNP:[251..259] Graduate)
        (NNP:[260..266] School) (IN:[267..269] of) (NNP:[270..277] Medical)
        (NNPS:[278..286] Sciences) (,:[286..287] ,) (NNP:[288..294] Kyushu)
        (NNP:[296..306] University) (,:[306..307] ,) (NNP:[308..315] Fukuoka)
        (,:[315..316] ,) (NNP:[317..322] Japan) (.:[322..323] .)))

;sentence 4 Span:327..671
;The immunohistochemical expression of beta-catenin, cyclin D1, Ki-67 and PCNA
; was Examined in 38 cases of sporadic extra-abdominal or abdominal-wall
;desmoid  tumours without familial adenomatous polyposis (FAP), to evaluate
;the hypothesis  that the accumulated beta-catenin within the nuclei could
;affect the regulation  of the cyclin D1 gene.
;[365..377]:gene-protein:"beta-catenin"
;[379..388]:gene-protein:"cyclin D1"
;[390..395]:gene-protein:"Ki-67"
;[400..404]:gene-protein:"PCNA"
;[434..458]:malignancy:"sporadic extra-abdominal"
;[462..493]:malignancy:"abdominal-wall desmoid  tumours"
;[502..532]:malignancy:"familial adenomatous polyposis"
;[534..537]:malignancy:"FAP"
;[589..601]:gene-protein:"beta-catenin"
;[656..665]:gene-rna:"cyclin D1"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[327..330] The) (JJ:[331..350] immunohistochemical)
          (NN:[351..361] expression))
      (PP (IN:[362..364] of)
        (NP (NN:[365..377] beta-catenin) (,:[377..378] ,)
           (NN:[379..385] cyclin) (NN:[386..388] D1)
          (,:[388..389] ,) (NN:[390..395] Ki-67) (CC:[396..399] and)
           (NN:[400..404] PCNA))))
    (VP (VBD:[406..409] was)
      (VP (VBN:[410..418] Examined)
        (NP-1 (-NONE-:[418..418] *))
        (PP (IN:[419..421] in)
          (NP
            (NP (CD:[422..424] 38) (NNS:[425..430] cases))
            (PP (IN:[431..433] of)
              (NP
                (NP
                  (NP
                    
                    (ADJP-2 (JJ:[434..442] sporadic))
                    (ADJP (AFX:[443..448] extra) (HYPH:[448..449] -)
                          (JJ:[449..458] abdominal))
                    (NML-3 (-NONE-:[458..458] *P*)))
                  (CC:[459..461] or)
                  (NP
                    (ADJP-2 (-NONE-:[461..461] *P*))
                    
                    (NML (JJ:[462..471] abdominal) (HYPH:[471..472] -)
                         (NN:[472..476] wall))
                    (NML-3 (JJ:[477..484] desmoid) (NNS:[486..493] tumours))))
                (PP (IN:[494..501] without)
                  (NP
                    (NP (JJ:[502..510] familial) (JJ:[511..522] adenomatous)
                        (NN:[523..532] polyposis))
                    (NP (-LRB-:[533..534] -LRB-) (NN:[534..537] FAP)
                        (-RRB-:[537..538] -RRB-))))))))
        (,:[538..539] ,)
        (S-PRP
          (NP-SBJ (-NONE-:[539..539] *))
          (VP (TO:[540..542] to)
            (VP (VB:[543..551] evaluate)
              (NP (DT:[552..555] the) (NN:[556..566] hypothesis)
                (SBAR (IN:[568..572] that)
                  (S
                    (NP-SBJ
                      (NP (DT:[573..576] the) (VBN:[577..588] accumulated)
                          (NN:[589..601] beta-catenin))
                      (PP-LOC (IN:[602..608] within)
                        (NP (DT:[609..612] the) (NNS:[613..619] nuclei))))
                    (VP (MD:[620..625] could)
                      (VP (VB:[626..632] affect)
                        (NP
                          (NP (DT:[633..636] the) (NN:[637..647] regulation))
                          (PP (IN:[649..651] of)
                            (NP (DT:[652..655] the)
                              (NML (NN:[656..662] cyclin) (NN:[663..665] D1))
                              (NN:[666..670] gene))))))))))))))
    (.:[670..671] .)))

;sentence 5 Span:672..796
;There was a statistically significant correlation between  beta-catenin
;accumulation and cyclin D1 overexpression (p=0.029).
;[731..743]:gene-protein:"beta-catenin"
;[761..770]:gene-protein:"cyclin D1"
(SENT
  (S
    (NP-SBJ (EX:[672..677] There))
    (VP (VBD:[678..681] was)
      (NP-PRD
        (NP (DT:[682..683] a)
          (ADJP (RB:[684..697] statistically) (JJ:[698..709] significant))
          (NN:[710..721] correlation))
        (PP (IN:[722..729] between)
          (NP
            (NP (NN:[731..743] beta-catenin) (NN:[744..756] accumulation))
            (CC:[757..760] and)
            (NP
              (NP (NN:[761..767] cyclin) (NN:[768..770] D1))
              (NN:[771..785] overexpression)))))
      (PRN (-LRB-:[786..787] -LRB-)
        (S
          (NP-SBJ (NN:[787..788] p))
          (VP (SYM:[788..789] =)
            (NP (CD:[789..794] 0.029))))
        (-RRB-:[794..795] -RRB-)))
    (.:[795..796] .)))

;sentence 6 Span:797..994
;Each group  with beta-catenin accumulation or cyclin D1 overexpression showed
;a higher  PCNA-LI than those without, the difference being statistically
;significant  (p=0.007, p=0.004, respectively).
;[814..826]:gene-protein:"beta-catenin"
;[843..852]:gene-protein:"cyclin D1"
;[885..889]:gene-protein:"PCNA"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[797..801] Each) (NN:[802..807] group))
      (PP (IN:[809..813] with)
        (NP
          (NP (NN:[814..826] beta-catenin) (NN:[827..839] accumulation))
          (CC:[840..842] or)
          (NP
            (NML (NN:[843..849] cyclin) (NN:[850..852] D1))
            (NN:[853..867] overexpression)))))
    (VP (VBD:[868..874] showed)
      (NP
        (NP (DT:[875..876] a) (JJR:[877..883] higher) (NN:[885..889] PCNA)
            (HYPH:[889..890] -) (NN:[890..892] LI))
        (PP (IN:[893..897] than)
          (NP
            (NP (DT:[898..903] those))
            (PP (IN:[904..911] without)))))
      (,:[911..912] ,)
      (S-ADV
        (NP-SBJ (DT:[913..916] the) (NN:[917..927] difference))
        (VP (VBG:[928..933] being)
          (ADJP-PRD (RB:[934..947] statistically) (JJ:[948..959] significant)
            (PRN (-LRB-:[961..962] -LRB-)
              (S
                (S
                  (NP-SBJ (NN:[962..963] p))
                  (VP (SYM:[963..964] =)
                    (NP (CD:[964..969] 0.007))))
                (,:[969..970] ,)
                (S
                  (NP-SBJ (NN:[971..972] p))
                  (VP (SYM:[972..973] =)
                    (NP (CD:[973..978] 0.004))))
                (,:[978..979] ,)
                (ADVP (RB:[980..992] respectively)))
              (-RRB-:[992..993] -RRB-))))))
    (.:[993..994] .)))

;sentence 7 Span:995..1154
;Differential PCR was also performed to detect  amplification of the cyclin D1
;gene and mutational analysis was undertaken for  exon 3 of the beta-catenin
;gene.
;[1063..1072]:gene-rna:"cyclin D1"
;[1122..1128]:variation-location:"exon 3"
;[1136..1148]:gene-rna:"beta-catenin"
(SENT
  (S
    (S
      (NP-SBJ-1 (JJ:[995..1007] Differential) (NN:[1008..1011] PCR))
      (VP (VBD:[1012..1015] was)
        (ADVP (RB:[1016..1020] also))
        (VP (VBN:[1021..1030] performed)
          (NP-1 (-NONE-:[1030..1030] *))
          (S-PRP
            (NP-SBJ (-NONE-:[1030..1030] *))
            (VP (TO:[1031..1033] to)
              (VP (VB:[1034..1040] detect)
                (NP
                  (NP (NN:[1042..1055] amplification))
                  (PP (IN:[1056..1058] of)
                    (NP (DT:[1059..1062] the)
                      (NML (NN:[1063..1069] cyclin) (NN:[1070..1072] D1))
                      (NN:[1073..1077] gene))))))))))
    (CC:[1078..1081] and)
    (S
      (NP-SBJ-2 (JJ:[1082..1092] mutational) (NN:[1093..1101] analysis))
      (VP (VBD:[1102..1105] was)
        (VP (VBN:[1106..1116] undertaken)
          (NP-2 (-NONE-:[1116..1116] *))
          (PP (IN:[1117..1120] for)
            (NP
              (NP (NN:[1122..1126] exon) (CD:[1127..1128] 3))
              (PP (IN:[1129..1131] of)
                (NP (DT:[1132..1135] the) (NN:[1136..1148] beta-catenin)
                    (NN:[1149..1153] gene))))))))
    (.:[1153..1154] .)))

;sentence 8 Span:1155..1235
;Amplification of the cyclin D1 gene was  observed in 13 out of 22 cases
;(59.1%).
;[1176..1185]:gene-rna:"cyclin D1"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1155..1168] Amplification))
      (PP (IN:[1169..1171] of)
        (NP (DT:[1172..1175] the)
          (NML (NN:[1176..1182] cyclin) (NN:[1183..1185] D1))
          (NN:[1186..1190] gene))))
    (VP (VBD:[1191..1194] was)
      (VP (VBN:[1196..1204] observed)
        (NP-1 (-NONE-:[1204..1204] *))
        (PP-LOC (IN:[1205..1207] in)
          (NP
            (NP (CD:[1208..1210] 13))
            (PP (IN:[1211..1214] out)
              (PP (IN:[1215..1217] of)
                (NP (CD:[1218..1220] 22) (NNS:[1221..1226] cases)
                  (PRN (-LRB-:[1227..1228] -LRB-)
                    (NP (CD:[1228..1232] 59.1) (NN:[1232..1233] %))
                    (-RRB-:[1233..1234] -RRB-)))))))))
    (.:[1234..1235] .)))

;sentence 9 Span:1236..1298
;There were nine-point mutations in 7 out  of 18 cases (38.9%).
;[1252..1267]:variation-type:"point mutations"
(SENT
  (S
    (NP-SBJ (EX:[1236..1241] There))
    (VP (VBD:[1242..1246] were)
      (NP-PRD
        (NML (CD:[1247..1251] nine) (HYPH:[1251..1252] -)
             (NN:[1252..1257] point))
        (NNS:[1258..1267] mutations))
      (PP (IN:[1268..1270] in)
        (NP
          (NP (CD:[1271..1272] 7))
          (PP (IN:[1273..1276] out)
            (PP (IN:[1278..1280] of)
              (NP (CD:[1281..1283] 18) (NNS:[1284..1289] cases))))
          (PRN (-LRB-:[1290..1291] -LRB-)
            (NP (CD:[1291..1295] 38.9) (NN:[1295..1296] %))
            (-RRB-:[1296..1297] -RRB-)))))
    (.:[1297..1298] .)))

;sentence 10 Span:1299..1394
;The distribution of beta-catenin mutation fell within a  wide range, from
;codon 21 to codon 67.
;[1319..1331]:gene-rna:"beta-catenin"
;[1373..1393]:variation-location:"codon 21 to codon 67"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1299..1302] The) (NN:[1303..1315] distribution))
      (PP (IN:[1316..1318] of)
        (NP (NN:[1319..1331] beta-catenin) (NN:[1332..1340] mutation))))
    (VP (VBD:[1341..1345] fell)
      (PP-LOC (IN:[1346..1352] within)
        (NP
          (NP (DT:[1353..1354] a) (JJ:[1356..1360] wide) (NN:[1361..1366] range))
          (,:[1366..1367] ,)
          (PP
            (PP (IN:[1368..1372] from)
              (NP (NN:[1373..1378] codon) (CD:[1379..1381] 21)))
            (PP (CD:[1382..1384] to)
              (NP (NN:[1385..1390] codon) (CD:[1391..1393] 67)))))))
    (.:[1393..1394] .)))

;sentence 11 Span:1395..1590
;In conclusion, beta-catenin nuclear  expression correlated with cyclin D1
;overexpression in sporadic desmoid tumours,  which could be an in vivo model
;system for the APC-beta-catenin-Tcf pathway.
;[1410..1422]:gene-protein:"beta-catenin"
;[1459..1468]:gene-protein:"cyclin D1"
;[1487..1511]:malignancy:"sporadic desmoid tumours"
;[1561..1564]:gene-protein:"APC"
;[1565..1577]:gene-protein:"beta-catenin"
;[1578..1581]:gene-protein:"Tcf"
(SENT
  (S
    (PP (IN:[1395..1397] In)
      (NP (NN:[1398..1408] conclusion)))
    (,:[1408..1409] ,)
    (NP-SBJ (NN:[1410..1422] beta-catenin) (JJ:[1423..1430] nuclear)
            (NN:[1432..1442] expression))
    (VP (VBD:[1443..1453] correlated)
      (PP-CLR (IN:[1454..1458] with)
        (NP
          (NML (NN:[1459..1465] cyclin) (NN:[1466..1468] D1))
          (NN:[1469..1483] overexpression)))
      (PP-LOC (IN:[1484..1486] in)
        (NP (JJ:[1487..1495] sporadic) (JJ:[1496..1503] desmoid)
            (NNS:[1504..1511] tumours)))
      (,:[1511..1512] ,)
      (SBAR-ADV
        (WHNP-1 (WDT:[1514..1519] which))
        (S
          (NP-SBJ-1 (-NONE-:[1519..1519] *T*))
          (VP (MD:[1520..1525] could)
            (VP (VB:[1526..1528] be)
              (NP-PRD
                (NP (DT:[1529..1531] an)
                  (ADJP (FW:[1532..1534] in) (FW:[1535..1539] vivo))
                  (NN:[1540..1545] model) (NN:[1546..1552] system))
                (PP (IN:[1553..1556] for)
                  (NP (DT:[1557..1560] the)
                    (NML
                      (NML (NN:[1561..1564] APC))
                      (PP (HYPH:[1564..1565] -)
                        (NP
                          (NP (NN:[1565..1577] beta-catenin))
                          (PP (HYPH:[1577..1578] -)
                            (NP (NN:[1578..1581] Tcf))))))
                    (NN:[1582..1589] pathway)))))))))
    (.:[1589..1590] .)))

;sentence 12 Span:1591..1709
;In  addition, beta-catenin mutations in desmoid tumours occurred at an
;unusually  wide range of sites within the gene.
;[1605..1617]:gene-rna:"beta-catenin"
;[1631..1646]:malignancy:"desmoid tumours"
;[1704..1708]:gene-rna:"gene"
(SENT
  (S
    (PP (IN:[1591..1593] In)
      (NP (NN:[1595..1603] addition)))
    (,:[1603..1604] ,)
    (NP-SBJ
      (NP (NN:[1605..1617] beta-catenin) (NNS:[1618..1627] mutations))
      (PP-LOC (IN:[1628..1630] in)
        (NP (JJ:[1631..1638] desmoid) (NNS:[1639..1646] tumours))))
    (VP (VBD:[1647..1655] occurred)
      (PP-LOC (IN:[1656..1658] at)
        (NP
          (NP (DT:[1659..1661] an)
            (ADJP (RB:[1662..1671] unusually) (JJ:[1673..1677] wide))
            (NN:[1678..1683] range))
          (PP (IN:[1684..1686] of)
            (NP
              (NP (NNS:[1687..1692] sites))
              (PP (IN:[1693..1699] within)
                (NP (DT:[1700..1703] the) (NN:[1704..1708] gene))))))))
    (.:[1708..1709] .)))

;section 13 Span:1710..1748
;Copyright 2001 John Wiley & Sons, Ltd.
(SEC
  (FRAG (NN:[1710..1719] Copyright) (CD:[1720..1724] 2001)
        (NNP:[1725..1729] John) (NNP:[1730..1735] Wiley) (CC:[1736..1737] &)
        (NNP:[1738..1742] Sons) (,:[1742..1743] ,) (NNP:[1744..1748] Ltd.)))

;section 14 Span:1752..1797
;PMID: 11592102 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1752..1756] PMID) (::[1756..1757] :) (CD:[1758..1766] 11592102)
        (NN:[1767..1768] -LSB-) (NNP:[1768..1774] PubMed) (::[1775..1776] -)
        (NN:[1777..1784] indexed) (IN:[1785..1788] for)
        (NNP:[1789..1797] MEDLINE-RSB-)))
